Lumatix Biotech

Lumatix Biotech is developing a light-controlled affinity matrix for an effective and rapid isolation of antibodies. Our new chromatography technology is intended to significantly advance antibody manufacturing, particular with regard to product quality as well as economic aspects. To achieve these ambitious goals and become a superior alternative to Protein A chromatography, we combine several proprietary technologies. The key innovation here is an affinity matrix with a light-controlled binding mode. By this means, the operator can easily capture antibodies in any user-defined buffer, making acidic elution obsolete. Have a look at our website for further information and follow us on LinkedIn for fresh updates on our journey. There is a lot to come! Imprint: https://www.lumatix.bio/imprint-data-protection/

Website

https://www.lumatix.bio

Externer Link zu Lumatix Biotech

Branche

Biotechnologieforschung

Größe

2–10 Beschäftigte

Hauptsitz

Garching bei München

Art

Kapitalgesellschaft (AG, GmbH, UG etc.)

Gegründet

2021